A randomised phase III clinical trial investigating the effect of FRAGMin Added to standard Therapy In patients with lung Cancer.

Trial Profile

A randomised phase III clinical trial investigating the effect of FRAGMin Added to standard Therapy In patients with lung Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Dalteparin sodium (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer; Small cell lung cancer; Thrombosis
  • Focus Therapeutic Use
  • Acronyms FRAGMATIC
  • Most Recent Events

    • 23 Dec 2015 Results published in the Journal of Clinical Oncology
    • 29 Oct 2013 Primary endpoint 'Overall-survival' has not been met.
    • 29 Oct 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top